Bruno Émond

1.4k total citations
94 papers, 788 citations indexed

About

Bruno Émond is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Bruno Émond has authored 94 papers receiving a total of 788 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Genetics, 20 papers in Pulmonary and Respiratory Medicine and 14 papers in Infectious Diseases. Recurrent topics in Bruno Émond's work include Chronic Lymphocytic Leukemia Research (28 papers), HIV/AIDS drug development and treatment (14 papers) and HIV-related health complications and treatments (13 papers). Bruno Émond is often cited by papers focused on Chronic Lymphocytic Leukemia Research (28 papers), HIV/AIDS drug development and treatment (14 papers) and HIV-related health complications and treatments (13 papers). Bruno Émond collaborates with scholars based in United States, Canada and Belgium. Bruno Émond's co-authors include Patrick Lefèbvre, Marie‐Hélène Lafeuille, Dominic Pilon, Kruti Joshi, Rhiannon Kamstra, Neeta Tandon, Laura Morrison, Carmine Rossi, Aurélie Côté‐Sergent and Prina Donga and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Bruno Émond

84 papers receiving 771 citations

Peers

Countries citing papers authored by Bruno Émond

Since Specialization

Citations

This map shows the geographic impact of Bruno Émond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruno Émond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruno Émond more than expected).

Fields of papers citing papers by Bruno Émond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruno Émond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruno Émond. The network helps show where Bruno Émond may publish in the future.

Co-authorship network of co-authors of Bruno Émond

This figure shows the co-authorship network connecting the top 25 collaborators of Bruno Émond. A scholar is included among the top collaborators of Bruno Émond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruno Émond. Bruno Émond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases 2025 ·Journal of Comparative Effectiveness Research ·Kerry A. Rogers, Benyam Muluneh, Zaina P. Qureshi, Jinghua He, (unknown), Zhijie Ding, (unknown), Priyanka Gogna, Bruno Émond, Michael G. Fradley	0
2	Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation 2024 ·PubMed ·Nilanjan Ghosh, Ruibin Wang, Zaina P. Qureshi, Zhijie Ding, Marie‐Hélène Lafeuille, Bruno Émond, (unknown), Jinghua He, (unknown), (unknown), Kerry A. Rogers	2
3	Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer 2024 ·Journal of Medical Economics ·Christine M. Bestvina, (unknown), Laura Morrison, Bruno Émond, Marie‐Hélène Lafeuille, (unknown), Patrick Lefèbvre, Andy He, (unknown)	5
4	Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors 2024 ·Drugs - Real World Outcomes ·Jessica A. Walsh, (unknown), Ruizhi Zhao, Natalie J. Shiff, Laura Morrison, Bruno Émond, (unknown), (unknown), Patrick Lefèbvre, (unknown), Soumya D. Chakravarty, Philip J. Mease	3
5	Respiratory Syncytial Virus–Related Complications and Healthcare Costs Among a Medicare-Insured Population in the United States 2023 ·Open Forum Infectious Diseases ·Jessica K. DeMartino, Marie‐Hélène Lafeuille, Bruno Émond, Carmine Rossi, Jingru Wang, (unknown), Patrick Lefèbvre, Girishanthy Krishnarajah	7
6	Incidence of cardiometabolic outcomes among people living with HIV‐1 initiated on integrase strand transfer inhibitor versus non‐integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States 2023 ·Journal of the International AIDS Society ·Peter F. Rebeiro, Bruno Émond, Carmine Rossi, Brahim Bookhart, Aditi Shah, (unknown), Marie‐Hélène Lafeuille, Prina Donga	14
7	Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia 2023 ·Patient Preference and Adherence ·Xiaoxiao Lu, Bruno Émond, Laura Morrison, (unknown), Patrick Lefèbvre, Marie‐Hélène Lafeuille, (unknown), Linda Wu, Zaina P. Qureshi, Ryan Jacobs	3
8	Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma 2023 ·Current Medical Research and Opinion ·Xiaoxiao Lu, Bruno Émond, Zaina P. Qureshi, Linda Wu, (unknown), (unknown), (unknown), Marie‐Hélène Lafeuille, Patrick Lefèbvre, Qing Huang, Kerry A. Rogers	1
9	Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib 2023 ·Future Oncology ·Ryan Jacobs, Xiaoxiao Lu, Bruno Émond, Laura Morrison, (unknown), Patrick Lefèbvre, Marie‐Hélène Lafeuille, (unknown), Linda Wu, Zaina P. Qureshi, Moshe Levy	2
10	Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data 2023 ·Clinical Genitourinary Cancer ·Umang Swami, (unknown), Mo Zhou, Shan Jiang, Jeri Kim, (unknown), François Laliberté, Bruno Émond, Neeraj Agarwal	6
11	Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis 2023 ·PharmacoEconomics - Open ·(unknown), Bruno Émond, Isabelle Ghelerter, (unknown), Marie‐Hélène Lafeuille, Patrick Lefèbvre, Lorie Ellis	5
12	Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1 2023 ·ClinicoEconomics and Outcomes Research ·Prina Donga, Bruno Émond, Carmine Rossi, Brahim Bookhart, (unknown), (unknown), (unknown), Marie‐Hélène Lafeuille	3
13	Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies 2023 ·Schizophrenia ·Christoph U. Correll, Carmela Benson, Bruno Émond, Charmi Patel, Marie‐Hélène Lafeuille, Dee Lin, Laura Morrison, Isabelle Ghelerter, Patrick Lefèbvre, Panagiotis Mavros	11
14	Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices 2023 ·Current Oncology ·Brandon S. Sheffield, (unknown), Bruno Émond, Marie‐Hélène Lafeuille, (unknown), Patrick Lefèbvre, Laura Morrison, (unknown), (unknown), Parneet Cheema	24
15	Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Émond, Sumeet Panjabi, (unknown), (unknown), (unknown), Marie‐Hélène Lafeuille, Patrick Lefèbvre, Qing Huang, Michael Y. Choi	10
16	Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab 2022 ·Current Medical Research and Opinion ·(unknown), Richard Melsheimer, Rachel H. Bhak, Patrick Lefèbvre, Maral DerSarkissian, Bruno Émond, (unknown), Catherine Nguyen, Melody Wu, Yinong Young‐Xu	5
17	Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy 2022 ·Infectious Diseases and Therapy ·Grace A. McComsey, Bruno Émond, Aditi Shah, Brahim Bookhart, Carmine Rossi, (unknown), Marie‐Hélène Lafeuille, Prina Donga	12
18	Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer 2022 ·Journal of Medical Economics ·(unknown), (unknown), Bruno Émond, Marie‐Hélène Lafeuille, (unknown), Patrick Lefèbvre, Laura Morrison	28
19	Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex 2019 ·Epilepsia Open ·(unknown), (unknown), Maureen P. Neary, Raluca Ionescu‐Ittu, Bruno Émond, Mei Sheng Duh, Floor E. Jansen, Bernard A. Zonnenberg	16
20	Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. 2018 ·PubMed ·Amy S. Paller, Rakesh Singh, Martin Cloutier, Marjolaine Gauthier‐Loiselle, Bruno Émond, Annie Guérin, Arijit Ganguli	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact